✦ LIBER ✦

Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand

✍ Scribed by Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Teerawattananon, Yot

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adherence to treatment with second-line

✍ Yood, Marianne Ulcickas; Oliveria, Susan A.; Cziraky, Mark; Hirji, Ishan; Hamdan 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 206 KB

Considerations for early switch to nilot

✍ Quintás-Cardama, Alfonso; Jabbour, Elias J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 277 KB

PCN60 Cost Effectiveness of Nilotinib, D

✍ Romero Martin, R.M.; Alvis Nelson, A.N.; De los Ríos Magalí, D.L.R.M.; Chávez Di 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN11 COST-UTILITY ANALYSIS OF DASATINIB

✍ JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN86 Cost-Utility Analysis of Nilotinib

✍ Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB